Board member and operationally focused Business Leader with demonstrated leadership experience in science, clinical and business operations roles within public and private Biotechnology and Medical Device organizations. Track record and strategic leadership in raising over $225M in outside funding from venture capital, strategic partners and private investors, along with experience in negotiating M&A deals that resulted in successful company exits, including the sale of Agilis to PTC Therapeutics for potential value of greater than $1B and a 16x return to investors. In addition to commercial leadership experience in preparing for launching products in the US and abroad (Upstaza, Pedmark, Lyric and Songbird), demonstrated track record of working with universities and academics in translating science into the clinic, managing R&D and drug development teams through regulatory approvals of BLA, INDs and 510ks. Recent experience in scaling a drug development company to support clinical trials and regulatory strategy and running the operations for a gene therapy company that competes in CNS and Rare Disease. Experience as a Board member to several innovative companies with efforts in stem cell therapy, biologics and gene therapy.

Stay In

The Know

Blank Form (#3)